<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522015</url>
  </required_header>
  <id_info>
    <org_study_id>RIVA</org_study_id>
    <secondary_id>eudraCT no: 2006-006166-42</secondary_id>
    <nct_id>NCT00522015</nct_id>
  </id_info>
  <brief_title>Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy</brief_title>
  <acronym>psp</acronym>
  <official_title>Rivastigmine (ExelonÂ®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to show that

        1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory
           function

        2. use of rivastigmine has a positive effect on apathy in PSP patients

        3. therapy with rivastigmine has a no positive benefit on speech and overall results of the
           MMST

        4. changes in motor activity are associated with changes in language and overall results of
           the in MMST
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date>February 2010</completion_date>
  <primary_completion_date>December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in neuropsychological assessments for memory and executive function, e.g. tested by &quot;Tower of London Test, CERAD Battery and Logical Memory Test (WMSR)&quot;</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in speech function and improvement of quality of life</measure>
    <time_frame>6 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivastigmine</intervention_name>
    <description>rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Exelon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of PSP

          -  willingness to participate in the study

          -  informed consent

          -  ability to speak

          -  no further CNS diseases

          -  written informed consent

          -  stable state of health

          -  ability to give informed consent, will checked by an independent physician

        Exclusion Criteria:

          -  alcohol abuses

          -  acute psychosis

          -  pregnancy or lactation

          -  known previous drug reaction or hypersensitivity of rivastigmine or other carbamate
             derivatives

          -  liver failure

          -  known sick sinus syndrome or excitation disturbance

          -  known ulcus ventriculi or duodenal ulcer

          -  known asthma or COPD

          -  seizures

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Berg, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Berg, Doctor</last_name>
    <phone>+49 7071 29 80438</phone>
    <email>daniela.berg@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inga Liepelt, Doctor</last_name>
    <phone>+ 49 7071 29 80424</phone>
    <email>inga.liepelt@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Berg, Doctor</last_name>
      <phone>+49 7071 29 80438</phone>
      <email>daniela.berg@uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2007</study_first_posted>
  <last_update_submitted>February 14, 2008</last_update_submitted>
  <last_update_submitted_qc>February 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Professor Dr. Berg</name_title>
    <organization>University hospital of Tuebingen</organization>
  </responsible_party>
  <keyword>PSP</keyword>
  <keyword>dementia</keyword>
  <keyword>neuropsychology</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

